Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

NCT05065866 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma
Hodgkin Lymphoma
Myeloma
Lymphocytic Leukemia

Interventions

DRUG: BMS-986345
DRUG: Duvelisib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]